MYCN drives a ferroptotic vulnerability in neuroblastoma

MYCN 导致神经母细胞瘤铁死亡的脆弱性

基本信息

  • 批准号:
    10736479
  • 负责人:
  • 金额:
    $ 69.67万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-01 至 2028-08-31
  • 项目状态:
    未结题

项目摘要

Project Summary: Apoptosis is a type of programmed cell death and has for a long time been appreciated to be a hallmark of cancer cells. In recent years, drugs targeting the apoptotic pathway, such as the FDA- approved BCL-2 inhibitor, venetoclax, have revolutionized therapy in cancers which have a particular vulnerability to targeting this pathway. A different programmed cell death pathway, ferroptosis, has recently been discovered. Understanding which cancers may be vulnerable to the induction of ferroptosis and which targetable molecules are involved could lead to a new wave of successful cancer therapy. MYCN-amplified neuroblastoma (NB) is one of the deadliest subtypes of pediatric cancer. Here in, we demonstrate that amplified MYCN drives an aberrant iron capture program in NB and increases intracellular cysteine biosynthesis and selenocysteine dependence through multiple mechanisms to detoxify reactive oxygen species (ROS) accumulation as a result of high cellular iron. The consequence of these MYCN-directed changes is a synthetic lethality to genetic or pharmaceutical targeting of the glutathione/glutathione peroxidase 4 (GPX4) pathway resulting in ferroptotic cell death. This grant aims to expand our understanding of how MYCN alters cysteine and selenocysteine production and ferroptotic inducing pathways to sustain an antioxidant defense and how these pathways may be exploited pharmaceutically to improve therapeutic responses in this recalcitrant tumor type. Specific Aims: Aim 1: Characterize the ability of MYCN to suppress ferroptosis in neuroblastoma Aim 2: Identification of synthetic lethal ferroptosis resistance mechanisms in MYCN-amplified neuroblastoma Aim 3: In MYCN-amplified neuroblastoma mouse models, evaluate novel ferroptotic combination therapies Study Design: Using well characterized isogenic cell lines and patient-derived xenograft cell cultures, we will mobilize expertise in selenocysteine biosynthesis (Copeland), pantothenate kinase inhibitors (Rock), and genomic screening of ferroptotic pathway modifiers (Olzmann) to better define the ferroptotic vulnerability in MYCN-amplified NB and to uncover novel sensitizers to ferroptotic inducers in MYCN-amplified NB. The goal of these experiments is to not only better understand how the MYCN oncogene hijacks cysteine for selenocysteine production to mount a defense against an oxidized phenotype, but to create new therapeutics to create better anti-ferroptotic approaches in MYCN-amplified NB. To this end, we will work with our preclinical mouse model expert (Koblinski) and a NB clinical investigator (Glod) to build the preclinical evidence of synthetic lethal new therapies into the clinic for refractory NB patients.
项目概述:细胞凋亡是一种程序性细胞死亡,长期以来一直受到重视, 是癌细胞的标志近年来,靶向凋亡途径的药物,如FDA- 已批准的BCL-2抑制剂维奈托克已经彻底改变了具有特定 针对这一途径的脆弱性。一种不同的程序性细胞死亡途径,铁凋亡,最近 被发现了解哪些癌症可能容易诱导铁凋亡, 靶向分子的参与可能会导致新一波成功的癌症治疗。MYCN扩增 神经母细胞瘤(NB)是儿科癌症中最致命的亚型之一。在这里,我们证明, 扩增的MYCN驱动NB中异常的铁捕获程序并增加细胞内半胱氨酸 生物合成和硒代半胱氨酸依赖通过多种机制解毒活性氧 物种(ROS)的积累作为高细胞铁的结果。这些MYCN导向的结果 变化是对谷胱甘肽/谷胱甘肽过氧化物酶的遗传或药物靶向的合成致死性 4(GPX 4)途径导致铁凋亡细胞死亡。这项资助旨在扩大我们对如何 MYCN改变半胱氨酸和硒代半胱氨酸的产生和铁凋亡诱导途径,以维持一种新的代谢途径。 抗氧化防御以及这些途径如何在药学上被利用来改善治疗 在这种恶性肿瘤中的反应。 具体目标: 目的1:描述MYCN抑制神经母细胞瘤中铁下垂的能力 目的2:MYCN扩增的神经母细胞瘤中合成致死性铁凋亡抗性机制的鉴定 目的3:在MYCN扩增的神经母细胞瘤小鼠模型中,评价新型铁结合疗法 研究设计:使用充分表征的等基因细胞系和患者来源的异种移植细胞培养物,我们将 动员硒代半胱氨酸生物合成(Copeland)、泛酸激酶抑制剂(Rock)方面的专业知识, 铁凋亡途径调节剂的基因组筛选(Olzmann),以更好地定义铁凋亡的脆弱性, MYCN扩增的NB和发现新的致敏剂,以铁蛋白诱导剂在MYCN扩增的NB。目标 这些实验的目的不仅是更好地了解MYCN癌基因如何劫持半胱氨酸, 硒代半胱氨酸的生产,以建立对氧化表型的防御,但创造新的治疗方法 以在MYCN扩增的NB中创建更好的抗铁凋亡方法。为此,我们将与我们的临床前 小鼠模型专家(Koblinski)和NB临床研究者(Glod),以建立 合成致命的新疗法进入临床难治性NB患者。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Anthony Charles Faber其他文献

Anthony Charles Faber的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Anthony Charles Faber', 18)}}的其他基金

SUMOylation disruption is toxic for SS18-SSX-driven synovial sarcoma
SUMO化破坏对 SS18-SSX 驱动的滑膜肉瘤具有毒性
  • 批准号:
    10736999
  • 财政年份:
    2023
  • 资助金额:
    $ 69.67万
  • 项目类别:
Neuroblastoma reliance on DNMT1 through amplified MYCN
神经母细胞瘤通过扩增 MYCN 依赖 DNMT1
  • 批准号:
    10410501
  • 财政年份:
    2020
  • 资助金额:
    $ 69.67万
  • 项目类别:
Neuroblastoma reliance on DNMT1 through amplified MYCN
神经母细胞瘤通过扩增 MYCN 依赖 DNMT1
  • 批准号:
    10159228
  • 财政年份:
    2020
  • 资助金额:
    $ 69.67万
  • 项目类别:
ABT-199 based therapies to treat neuroblastoma
基于 ABT-199 的神经母细胞瘤疗法
  • 批准号:
    9899951
  • 财政年份:
    2017
  • 资助金额:
    $ 69.67万
  • 项目类别:
ABT-199 based therapies to treat neuroblastoma
基于 ABT-199 的神经母细胞瘤疗法
  • 批准号:
    9289519
  • 财政年份:
    2017
  • 资助金额:
    $ 69.67万
  • 项目类别:
Assessing BIM expression as a cause and marker for resistance to targeted therapi
评估 BIM 表达作为靶向治疗耐药性的原因和标志
  • 批准号:
    8916050
  • 财政年份:
    2014
  • 资助金额:
    $ 69.67万
  • 项目类别:
Developmental Therapeutics Research Program
发育治疗研究计划
  • 批准号:
    10628432
  • 财政年份:
    1995
  • 资助金额:
    $ 69.67万
  • 项目类别:

相似海外基金

Enhancing gamete cryoprotective properties of graphene oxide by dual functionalization with antioxidants and non-penetrating cryoprotectant molecules
通过抗氧化剂和非渗透性冷冻保护剂分子的双重功能化增强氧化石墨烯的配子冷冻保护特性
  • 批准号:
    24K18002
  • 财政年份:
    2024
  • 资助金额:
    $ 69.67万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
SBIR Phase I: Sustainable antioxidants for industrial process fluids
SBIR 第一阶段:工业过程流体的可持续抗氧化剂
  • 批准号:
    2222215
  • 财政年份:
    2023
  • 资助金额:
    $ 69.67万
  • 项目类别:
    Standard Grant
Development of a new bone augmentation method that enables long-term survival and long-term functional expression of transplanted cells by antioxidants
开发一种新的骨增强方法,通过抗氧化剂使移植细胞能够长期存活和长期功能表达
  • 批准号:
    23K09272
  • 财政年份:
    2023
  • 资助金额:
    $ 69.67万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Non-Invasive Probing Cellular Oxidative Stress and Antioxidants Therapeutic Effectiveness
非侵入性探测细胞氧化应激和抗氧化剂的治疗效果
  • 批准号:
    10652764
  • 财政年份:
    2023
  • 资助金额:
    $ 69.67万
  • 项目类别:
Mitochondria-targeting Novel Cationic Hydrazone Antioxidants for the Treatment of Preeclampsia
线粒体靶向新型阳离子腙抗氧化剂用于治疗先兆子痫
  • 批准号:
    10730652
  • 财政年份:
    2023
  • 资助金额:
    $ 69.67万
  • 项目类别:
Latent Antioxidants for Environmentally Responsible Polymer Formulations
用于环保聚合物配方的潜在抗氧化剂
  • 批准号:
    RGPIN-2018-04107
  • 财政年份:
    2022
  • 资助金额:
    $ 69.67万
  • 项目类别:
    Discovery Grants Program - Individual
Contribution of antioxidants to regeneration of rotator cuff insertion
抗氧化剂对肩袖插入再生的贡献
  • 批准号:
    22K16720
  • 财政年份:
    2022
  • 资助金额:
    $ 69.67万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of different doses of antioxidants(Vitamin E) intake on exercise induced oxidative stress, antioxidative capacity and chronic inflammation
不同剂量抗氧化剂(维生素E)摄入对运动引起的氧化应激、抗氧化能力和慢性炎症的影响
  • 批准号:
    22K11609
  • 财政年份:
    2022
  • 资助金额:
    $ 69.67万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Polyunsaturated fatty acid (PUFA), inflammation and antioxidants
多不饱和脂肪酸 (PUFA)、炎症和抗氧化剂
  • 批准号:
    RGPIN-2019-05674
  • 财政年份:
    2022
  • 资助金额:
    $ 69.67万
  • 项目类别:
    Discovery Grants Program - Individual
Suppressed methemoglobin formation of artificial red cell by liposomal antioxidants and its mechanism.
脂质体抗氧化剂抑制人工红细胞高铁血红蛋白形成及其机制
  • 批准号:
    22K12824
  • 财政年份:
    2022
  • 资助金额:
    $ 69.67万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了